UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 37

Sortiert nach

Efficacy of the AS04-Adjuvanted HPV16/18 Vaccine: Pooled Analysis of the Costa Rica Vaccine and PATRICIA Randomized Controlled Trials

JNCI : Journal of the National Cancer Institute, 2020-08, Vol.112 (8), p.818-828

2020

Link zum Volltext

Verfügbarkeit prüfen

A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years

Human vaccines & immunotherapeutics, 2019-08, Vol.15 (7-8), p.1970-1979

2019

Link zum Volltext

Verfügbarkeit prüfen

Ten‐year immune persistence and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in females vaccinated at 15–55 years of age

Cancer medicine (Malden, MA), 2017-11, Vol.6 (11), p.2723-2731

2017

Link zum Volltext

Verfügbarkeit prüfen

Persistence of antibodies 20 y after vaccination with a combined hepatitis A and B vaccine

Human vaccines & immunotherapeutics, 2017-05, Vol.13 (5), p.972-980

2017

Link zum Volltext

Verfügbarkeit prüfen

Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults

npj vaccines, 2023-05, Vol.8 (1), p.75-75

2023

Link zum Volltext

Verfügbarkeit prüfen

Characterization of 16 human G protein-coupled receptors expressed in baculovirus-infected insect cells

Protein expression and purification, 2005-11, Vol.44 (1), p.65-74

2005

Link zum Volltext

Verfügbarkeit prüfen

A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus vaccine in a dengue non-endemic country

Vaccine, 2023-02, Vol.41 (7), p.1398-1407

2023

Link zum Volltext

Verfügbarkeit prüfen

Effect of the Tetravalent Dengue Vaccine TAK-003 on Sequential Episodes of Symptomatic Dengue

The American journal of tropical medicine and hygiene, 2023-04, Vol.108 (4), p.722-726

2023

Link zum Volltext

Verfügbarkeit prüfen

Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1–2 randomised controlled trial

The Lancet infectious diseases, 2022-07, Vol.22 (7), p.1062-1075

2022

Link zum Volltext

Verfügbarkeit prüfen

Persistence of HBsAg‐specific antibodies and immune memory two to three decades after hepatitis B vaccination in adults

Journal of viral hepatitis, 2019-09, Vol.26 (9), p.1066-1075

2019

Link zum Volltext

Verfügbarkeit prüfen

Reply to Poddighe

The Journal of infectious diseases, 2017-09, Vol.216 (6), p.783-785

2017

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of AS04-Adjuvanted Vaccine Against Human Papillomavirus (HPV) Types 16 and 18 in Clearing Incident HPV Infections: Pooled Analysis of Data From the Costa Rica Vaccine Trial and the PATRICIA Study

The Journal of infectious diseases, 2021-05, Vol.223 (9), p.1576-1581

2021

Link zum Volltext

Verfügbarkeit prüfen

Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9–14 Years: A Randomized Trial

The Journal of infectious diseases, 2017-06, Vol.215 (11), p.1711-1719

2017

Link zum Volltext

Verfügbarkeit prüfen

Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine

The Journal of infectious diseases, 2019-05, Vol.219 (11), p.1799-1803

2019

Link zum Volltext

Verfügbarkeit prüfen

Persistence of HB sAg‐specific antibodies and immune memory two to three decades after hepatitis B vaccination in adults

Journal of viral hepatitis, 2019-09, Vol.26 (9), p.1066-1075

2019

Link zum Volltext

Verfügbarkeit prüfen

97. Tetravalent Dengue Vaccine (TAK-003) Development Program: A Bird’s Eye View

Open forum infectious diseases, 2021-12, Vol.8 (Supplement_1), p.S61-S61

2021

Link zum Volltext

Verfügbarkeit prüfen

Safety and immunogenicity of a respiratory syncytial virus prefusion F protein (RSVPreF3) candidate vaccine in older Japanese adults: A phase I, randomized, observer-blind clinical trial

Respiratory investigation, 2023-03, Vol.61 (2), p.261-269

2023

Link zum Volltext

Verfügbarkeit prüfen

Long‐term persistence of immune response to the AS04‐adjuvanted HPV‐16/18 vaccine in Chinese girls aged 9‐17 years: Results from an 8‐9‐year follow‐up phase III open‐label study

Asia-Pacific journal of clinical oncology, 2020-12, Vol.16 (6), p.392-399

2020

Link zum Volltext

Verfügbarkeit prüfen

Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial

Human vaccines & immunotherapeutics, 2015, Vol.11 (7), p.1689-1702

2015

Link zum Volltext

Verfügbarkeit prüfen

Letter to the Editor in response to O.M. Bautista, A. Luxembourg. Deconstructing the m easure of v accine e fficacy a gainst d isease i rrespective of HPV in HPV v accine c linical t rials. Contemporary Clinical Trials 47 (2016) 254–258

Contemporary clinical trials, 2016

2016

Link zum Volltext

Verfügbarkeit prüfen

Letter to the Editor in response to O.M. Bautista, A. Luxembourg. Deconstructing the measure of vaccine efficacy against disease irrespective of HPV in HPV vaccine clinical trials. Contemporary Clinical Trials 47 (2016) 254–258

Contemporary clinical trials, 2017-03, Vol.54, p.106-107

2017

Link zum Volltext

Verfügbarkeit prüfen

Immunogenicity and safety of the AS04-HPV-16/18 and HPV-6/11/16/18 human papillomavirus vaccines in asymptomatic young women living with HIV aged 15–25 years: A phase IV randomized comparative study

EClinicalMedicine, 2020-06, Vol.23, p.100353-100353, Article 100353

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 37

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(37)

Publikationsform

Artikel
(37)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(22)
Science & Technology
(22)
Humans
(15)
Vaccines
(12)
Female
(11)
Immunogenicity
(10)
Immunology
(9)
Safety
(9)
Vaccination
(9)
Adolescent
(8)
Human Papillomavirus
(8)
Adult
(6)
Human Papillomavirus 16 - Immunology
(6)
Human Papillomavirus 18 - Immunology
(6)
Immune Response
(6)
Infectious Diseases
(6)
Papillomavirus Infections - Prevention & Control
(6)
Papillomavirus Vaccines - Immunology
(6)
Antibodies
(5)
Bacterial Outer Membrane Proteins
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Efficacy of the AS04-Adjuvanted HPV16/18 Vaccine: Pooled Analysis of the Costa Rica Vaccine and PATRICIA Randomized Controlled Trials

A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years

Ten‐year immune persistence and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in females vaccinated at 15–55 years of age

Persistence of antibodies 20 y after vaccination with a combined hepatitis A and B vaccine

Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults

Characterization of 16 human G protein-coupled receptors expressed in baculovirus-infected insect cells

A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus vaccine in a dengue non-endemic country

Effect of the Tetravalent Dengue Vaccine TAK-003 on Sequential Episodes of Symptomatic Dengue

Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1–2 randomised controlled trial

Persistence of HBsAg‐specific antibodies and immune memory two to three decades after hepatitis B vaccination in adults

Reply to Poddighe

Efficacy of AS04-Adjuvanted Vaccine Against Human Papillomavirus (HPV) Types 16 and 18 in Clearing Incident HPV Infections: Pooled Analysis of Data From the Costa Rica Vaccine Trial and the PATRICIA Study

Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9–14 Years: A Randomized Trial

Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and 4vHPV vaccine administered according to two- or three-dose schedules in girls aged 9–14 years: Results to month 36 from a randomized trial

Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine

Persistence of HB sAg‐specific antibodies and immune memory two to three decades after hepatitis B vaccination in adults

97. Tetravalent Dengue Vaccine (TAK-003) Development Program: A Bird’s Eye View

Safety and immunogenicity of a respiratory syncytial virus prefusion F protein (RSVPreF3) candidate vaccine in older Japanese adults: A phase I, randomized, observer-blind clinical trial

Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial

Efficacy and Safety of a Tetravalent Dengue Vaccine (TAK-003) in Children With Prior Japanese Encephalitis or Yellow Fever Vaccination

Long‐term persistence of immune response to the AS04‐adjuvanted HPV‐16/18 vaccine in Chinese girls aged 9‐17 years: Results from an 8‐9‐year follow‐up phase III open‐label study

Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial

Letter to the Editor in response to O.M. Bautista, A. Luxembourg. Deconstructing the m easure of v accine e fficacy a gainst d isease i rrespective of HPV in HPV v accine c linical t rials. Contemporary Clinical Trials 47 (2016) 254–258

Letter to the Editor in response to O.M. Bautista, A. Luxembourg. Deconstructing the measure of vaccine efficacy against disease irrespective of HPV in HPV vaccine clinical trials. Contemporary Clinical Trials 47 (2016) 254–258

Immunogenicity and safety of the AS04-HPV-16/18 and HPV-6/11/16/18 human papillomavirus vaccines in asymptomatic young women living with HIV aged 15–25 years: A phase IV randomized comparative study

Suchergebnisse filtern